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Plasticity of the Mycobacterium tuberculosis
respiratory chain and its impact on tuberculosis
drug development
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The viability of Mycobacterium tuberculosis (Mtb) depends on energy generated by its
respiratory chain. Cytochrome bc1-aa3 oxidase and type-2 NADH dehydrogenase (NDH-2)
are respiratory chain components predicted to be essential, and are currently targeted for
drug development. Here we demonstrate that an Mtb cytochrome bc1-aa3 oxidase deletion
mutant is viable and only partially attenuated in mice. Moreover, treatment of Mtb-infected
marmosets with a cytochrome bc1-aa3 oxidase inhibitor controls disease progression and
reduces lesion-associated inflammation, but most lesions become cavitary. Deletion of both
NDH-2 encoding genes (Δndh-2 mutant) reveals that the essentiality of NDH-2 as shown in
standard growth media is due to the presence of fatty acids. The Δndh-2mutant is only mildly
attenuated in mice and not differently susceptible to clofazimine, a drug in clinical use
proposed to engage NDH-2. These results demonstrate the intrinsic plasticity of Mtb’s
respiratory chain, and highlight the challenges associated with targeting the pathogen’s
respiratory enzymes for tuberculosis drug development.
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In 2012, bedaquiline (BDQ) became the first new drugapproved for treatment of tuberculosis (TB) in ~40 years1. Theproposed mode of action of BDQ entails a perturbation of
Mtb’s ATP synthase causing lethal proton cycling2. To function,
ATP synthase activity requires proton motive force (pmf) created
by the respiratory chain (RC), which in Mtb consists of nine
respiratory dehydrogenases and four terminal oxidoreductases3.
Maintenance of pmf is essential for Mtb’s viability in replicative
and non-replicative states4, which highlights Mtb’s RC as a pro-
mising cell process for drug development. Two RC components
were predicted to be essential for optimal growth of Mtb, namely
the cytochrome bc1-aa3 oxidase, encoded by ctaB, ctaC, ctaD, and
ctaE-qcrCAB, and a type-2 NADH dehydrogenase (NDH-2)
encoded by two genes, ndh and ndhA5–7. Recently, ndh was
shown to be dispensable for growth of Mtb8, but a mutant devoid
of NDH-2 activity - due to deletion of both ndh and ndhA - was
predicted to be not viable8.
Cytochrome bc1-aa3 oxidase and NDH-2 also seem susceptible
to inhibition by drug-like molecules and are being pursued as
targets for TB drug development. Several groups have identified
imidazopyridine amides that likely target QcrB9–11. Most notably,
Q203, an imidazopyridine amide, was originally reported to be
efficacious in the mouse model of TB10, and it is currently being
evaluated in clinical trials (ClinicalTrials.gov NCT02530710;
NCT02858973; NCT03563599). Most recently, the arylvinylpi-
perazine amides were described as a new class of potent QcrB
inhibitors12. NDH-2 has been proposed as the molecular target of
several potent antimycobacterial compounds including the phe-
nothiazines13 and is thought to activate clofazimine (CFZ)14, a
drug that has been used to treat leprosy for decades and is
occasionally included in the treatment of multi-drug resistant
(MDR) TB. Other compounds with antimycobacterial activity
that have been reported to inhibit NDH-2 include quinolinyl
pyrimidines15, compounds with a tetrahydroindazole or a thio-
quinazoline core16, and 2-mercapto-quinazolinones17. Further-
more, it has been shown that quinolinequinones are bactericidal
due to an activation of NDH-2 activity18. This is consistent with a
report indicating that activation of the respiratory chain can
accelerate the cidality of TB drugs19.
It is, nevertheless, not obvious why Mtb should require either
cytochrome bc1-aa3 oxidase or NDH-2 to grow. The Mtb genome
encodes an alternative, oxygen-dependent respiratory oxidor-
eductase, the cytochrome bd oxidase, which can compensate for
the loss of the cytochrome bc1-aa3 in M. smegmatis20 and Mtb,
suggesting that Q203 might not be able to prevent growth of Mtb
in mice, unless cytochrome bd oxidase is also inhibited21. It was
furthermore shown that electrons can be re-routed by Mtb to
cytochrome bd oxidase when cytochrome bc1-aa3 oxidase is
inhibited22. Cytochrome bd oxidase is strongly upregulated in
hypoxia suggesting that essentiality of either system may be
dependent upon oxygen tension23,24. To integrate the somewhat
contradictory data on essentiality of cytochrome bc1-aa3 oxidase,
it has been proposed that cytochrome bd oxidase is sufficient to
maintain cell viability when cytochrome bc1-aa3 oxidase is not
functional, but it is incapable of sustaining growth of Mtb21. The
predicted essentiality of NDH-2 activity is surprising becauseMtb
can express a type-1 NADH dehydrogenase (NDH-1), which is
similar to the eukaryotic respiratory complex 1 and thus could, at
least in principle, compensate for the loss of NDH-2 activity3.
Here, we combine conditional gene silencing, chemical genet-
ics, and treatment efficacy studies to determine the consequences
of inhibitingMtb’s cytochrome bc1-aa3 oxidase or NDH-2 in vitro
and during infections of mice and marmosets.
Results
The cytochrome bc1-aa3 and bd oxidases of Mtb are redundant.
We constructed three TetOFF mutants, in which anhydrote-
tracycline (atc) represses expression of ctaE-qcrCAB, ctaC, and
ctaD, respectively. Atc reduced the growth rate of these mutants,
but it did not prevent their growth (Supplementary Fig. 1A–C),
supporting the hypothesis that inactivation of the bc1-aa3 com-
plex might not prevent growth of Mtb. This conclusion was
confirmed by isolating deletion mutants for ctaE-qcrCAB, ctaC,
and ctaD. These mutants grew with rates similar to those
observed after silencing cytochrome bc1-aa3 subunits by the
TetOFF system (Supplementary Fig. 1D–F). Deletion of the tar-
geted genes was confirmed by whole genome sequencing (WGS),
which also allowed the screening for possible secondary muta-
tions (Supplementary Fig. 2, and Supplementary Table 1). None
of the mutants carried additional mutations predicted to impact
growth and genetic complementation rescued the slow growth
phenotype of all deletion mutants.
In mice ΔctaE-qcrCAB grew slowly during the acute phase of
infection, but by day 28 post infection the strain had reached the
same titer as wild-type Mtb (WT) and showed no pronounced
persistence defect thereafter (Fig. 1). ΔctaC presented an even
slower growth rate than ΔctaE-qcrCAB, reaching maximum titers
in the lung at day 56 (~1 log lower than the WT), and in spleens
at day 112 (~1 log lower than the WT) (Supplementary Fig. 3).
To understand the mechanisms that allow Mtb to grow in the
absence of cytochrome bc1-aa3 oxidase, we analyzed the mRNA
levels of nuoA (NDH-1), ndh and ndhA (NDH-2), ctaC
(cytochrome aa3 oxidase), qcrA (cytochrome bc1 reductase), cydA
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Fig. 1 The cytochrome bc1-aa3 complex is dispensable for growth and persistence of Mtb in mice. Growth and persistence of ΔctaE-qcrCAB in mouse lungs
(a) and spleens (b). Data are averages of CFUs from at least three mice per time point. Error bars correspond to standard deviation. “Comp” stands for
complemented. Statistical significance was assessed by one-way ANOVA followed by post hoc test (Tukey test; GraphPad Prism). *P < 0.05; ns - not
significant. Source data are provided as a Source Data file
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(cytochrome bd oxidase), and atpE (ATP synthase) from cultures
grown to mid-exponential phase in standard media (Supplemen-
tary Fig. 4A–D). Ndh and cydA were both consistently
upregulated in response to genetic inactivation of cytochrome
bc1-aa3 oxidase. Induction of cydA, which also occurred in
response to treatment of Mtb with Q20311, suggested that
elevated expression of the cytochrome bd oxidase compensated
for the lack of cytochrome bc1-aa3 oxidase. We therefore
constructed Mtb ΔcydABDC ctaE-qcrCAB-TetOFF which allowed
us to conditionally silence ctaE-qcrCAB in a cytochrome bd
oxidase deletion mutant (Supplementary Fig. 5). ΔcydABDC ctaE-
qcrCAB-TetOFF did not grow after silencing of ctaE-qcrCAB with
atc in vitro (Supplementary Fig. 1G). Doxycycline (doxy), which
is used to regulate Mtb gene expression during animal infection,
had a drastic impact on this strain in mice (Supplementary
Fig. 6A, B). When doxy was administered from day 1, the strain
was unable to establish infection; when administered from day 35,
CFU decreased by approximately five orders of magnitude over
the next 35 days. As reported previously21, we observed no
growth or persistence defects for ΔcydABDC, in which only the
cytochrome bd oxidase was inactivated (Supplementary Fig. 1H,
Supplementary Fig. 6C, D). In summary, these data demonstrate
that Mtb requires the cytochrome bc1-aa3 supercomplex to
achieve optimal growth rates and maximal titers in mice, but this
RC complex is not essential for growth or persistence as long as
Mtb can express cytochrome bd oxidase.
ND-10885 controlled infection, but increased cavitation. The
findings described above raised concerns about the use of cyto-
chrome bc1-aa3 oxidase inhibitors as stand-alone drugs to treat
TB, adding to a previous report showing that Q203 alone was not
able to stop Mtb’s growth in mice21. It is, however, worth noting
that Q203 might synergize in vivo with approved TB drugs, such
as rifampicin or pyrazinamide25, thus being a possible suitable
candidate for combination therapies. We therefore sought to
determine efficacy of a cytochrome bc1-aa3 oxidase inhibitor in an
animal model that reproduces more aspects of human TB
pathogenesis than the mouse model.
TB disease includes a broad spectrum of lesion types that
evolve in response to host attempts to limit the infection. These
lesion types presentMtb with a variety of different carbon sources
to be metabolized under a range of oxygen tensions26. Hence, we
selected a non-human primate model of TB disease in common
marmosets27,28 to test Q203 efficacy. Initial experiments with
Q203 failed to produce a formulation that gave acceptable
exposure in these monkeys. A structural analog of Q203
(Supplementary Fig. 7) with improved pharmacokinetics and
solubility properties (ND-10885)29, with an MIC of 0.1 μM
against CDC1551, theMtb strain used for infection of marmosets,
was therefore employed and found to give good exposure in
marmosets following oral administration with co-administration
of a CYP450 inhibitor, 1-aminobenzotriazole (ABT)30,31 (Sup-
plementary Figs. 8A and 9). Tissue distribution studies in lung
lesion compartments revealed adequate concentrations in all
lesions and favorable partitioning in laser-captured necrotic foci
and cavity caseum (Supplementary Fig. 8B–D).
Marmosets were infected by low-dose aerosol and disease
development was monitored by bi-weekly 2-[18F]-fluoro-2-
deoxyglucose (FDG) PET-CT scanning as previously described28.
After 50–55 days of infection, moderate to large lesions were
clearly visible in these animals by PET-CT imaging and treatment
with ND-10885 was initiated. Disease progression was arrested by
treatment as illustrated in Fig. 2a, which shows the total uptake of
FDG for each of the individual lesions in a single animal.
Figure 2b shows the total volume of each lesion within the range
of –100 to 200 Hounsfeld Units, which we have previously shown
represents the majority of radiodense tissue associated with TB
lesions28. Figure 2c, d show heat maps of those same two
parameters for all five animals illustrating that most lesions
within these animals showed reduced FDG uptake, indicating
reduced inflammation, while maintaining a consistent volume of
hard lesion density.
After 2 months of treatment, animals were humanely killed
and individual lesions were dissected for enumeration of bacterial
CFU and detailed histology. The CFU and gross pathology results
are shown in Fig. 3 in comparison with two other treatment
regimens previously reported: the standard care treatment for TB
patients isoniazid-rifampicin-pyrazinamide-ethambutol (HRZE),
and an earlier 2-year regimen associated with unacceptable
relapse rates in TB patients that comprised streptomycin-
isoniazid (HS)28. CFU and lesion numbers were substantially
higher in the animals treated with ND-10885 compared with a
two-month treatment with either HRZE, or HS. None of the
bacteria recovered from the infected animals were resistant to
ND-10885 (Supplementary Table 2). Most strikingly, as illu-
strated by the shape of the symbols in Fig. 3a, approximately half
of lesions were characterized as cavitary on the basis of gross
pathology in animals treated with ND-10885 (inset is the
comparison of the gross pathology findings by treatment arm
for all three treatments). Histological examination of these lesions
revealed that nearly all lesions had a well-developed fibrous cuff
surrounding a central area of necrosis. Lesions characterized as
“caseous-fibrotic” at gross pathology appear to be identical to
cavities that had not yet liquefied and drained into the airways.
Figure 3b displays the PET/CT findings from one of these animals
and shows the development and drainage of the liquefied interior
into the airways during treatment with ND-10885. Finally, Fig. 3c
shows the histopathology of the cavity from the left superior lung
lobe cavity shown in Fig. 3b revealing a large, partially liquefied
lesion with areas of caseous necrosis surrounded by a dense
fibrotic cuff. This 8-mm lesion contained ~224,000 bacteria and
these bacteria were easily observable within the necrotic region of
the lesion by acid-fast staining (Fig. 3c, lower panel). Taken
together, these data demonstrate that treatment with Mtb’s
cytochrome bc1-aa3 oxidase inhibitor ND-10885 effectively
controlled the infection in that no new lesions appeared and
inflammation was reduced, but only a subset of organisms was
affected while those present in existing granulomas flourished
resulting in exacerbation of disease by increasing cavitation.
Essentiality of NDH-2 is conditional. Besides cytochrome bc1-
aa3 oxidase, NDH-2 is the second component of Mtb’s RC that is
considered as a target for TB drug development. However, efforts
to utilize its inhibition might be plagued by the same functional
redundancy that affects inhibition of cytochrome bc1-aa3 oxidase.
The Mtb genome can express two NDH-2 enzymes, encoded by
ndh and ndhA, and one NDH-1, encoded by the nuo operon3. To
evaluate the consequences of inhibiting both NDH-2 enzymes we
constructed Mtb ndh-2-TetOFF, in which ndh has been deleted
and ndhA can be silenced with atc. ndh-2-TetOFF did not grow in
standard liquid and solid media containing atc (Fig. 4a). Sur-
prisingly, atc had no effect on ndh-2-TetOFF in minimal media
devoid of fatty acids (Fig. 4b). We confirmed that essentiality of
NDH-2 is conditional using fatty-acid-free media by isolating
Mtb Δndh-2, in which ndh and ndhA have both been deleted.
Deletion of both NDH-2 encoding genes was confirmed by WGS
(Supplementary Fig. 10). Transformation with an intact copy of
ndh rescued Δndh-2 (see below), which suggests that the poly-
morphisms identified in Δndh-2 (Supplementary Table 1) are not
responsible for the phenotypes of Δndh-2. Δndh-2 grew like WT
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in liquid media without fatty acids, but survival was compromised
during gradual oxygen depletion (Fig. 4c). In mouse lungs, Δndh-
2 grew to titers that were, on average, 26-fold lower than for WT
(Fig. 4d). The mutant was less attenuated in spleens (Fig. 4e).
To assess for possible compensatory effects to the lack of a
functional NDH-2 enzyme we analyzed the transcripts levels of
nuoA, ndh, ndhA, qcrA, ctaC, cydA, and atpE in cultures grown to
mid-exponential phase in fatty-acid-free modified Sauton’s
media. Apart from the expected absence of ndh and ndhA
transcripts in Δndh-2, we did not observe differences between the
mutant and the WT (Supplementary Fig. 4E, F). To test if Δndh-2
is viable due to compensation by NDH-1 we determined
susceptibility of Δndh-2 to the NDH-1 inhibitor rotenone.
Rotenone was inactive against WT Mtb, which agrees with
previous data;4 but rotenone prevented growth of and was
bactericidal for Δndh-2 (Fig. 5a, b). We conclude that NDH-1 and
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Fig. 2 ND10885 treatment of M. tuberculosis infected marmosets. a Total lesion glycolysis within each individual lesion for a single animal. The timeline
begins 41 days post-infection and treatment within this animal begins at Day 55. Most lesions appear to become less FDG avid within the first 2 weeks of
treatment and then stabilize or progress for 2-month treatment period. In untreated animals all lesions would have continued to progress. Symbols
represent the mean and error bars of the standard deviation of three independent readers. b Hard lesion volume (−100 HU to +200 HU) in most lesions
the volume growth slows when treatment starts but it is maintained at the same level as the last pretreatment scan (Day 55). Symbols represent the mean
and error bars the standard deviation of three independent readers. c Heat map of the lesion-level total PET data for all five animals that were treated with
ND10885. Timepoint 2 is the equivalent of Day 55 in panels (a) and (b), the starting point of drug administration. Most lesions in these animals behave in
the same way as those shown in panel (a), the total inflammation in each decreases from timepoint 2 to the end of therapy. For each lesion the three bars
represent SUVmax, SUVmean and total lesion glycolysis. d The lesional volume change in each lesion for all animals across the same treatment period.
Again similar to the pattern shown in panel (b) volume plateaus in most lesions at timepoint 3, 2 weeks after the initiation of treatment. For each lesion two
bars are shown, the left bar indicates volume in the hard range (−100 to + 200 HU) while on the right the total lesion volume (from −500 to + 200 HU)
is shown. Source data are provided as a Source Data file
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Fig. 3 ND10885 treatment in infected marmosets allows cavity formation. a Lesion pathology at necropsy for marmosets treated with three different drug
regimens. HRZE, isoniazid, rifampicin, pyrazinamide, and ethambutol; HS, isoniaizid, and streptomycin (CFU data and PK have been previously published
for both control arms; ref. 28). Each number refers to an individual animal and each symbol above it describes the pathology of each individual lesion within
that animal, the size of the symbol is according to the size of the lesion, small symbols are 1 mm lesions and the largest symbols are ~10mm lesions. The
inset bar graph summarizes the same data according to the total percentage of lesions in each of the three pathology types. Source data are provided as a
Source Data file. b an example of PET/CT images of one animal treated with ND10885 over time, the first image is 37 days after infection with a low-dose
aerosol ofM. tuberculosis, the second image is day 51 and immediately after that image the animal began receiving ND10885. There are two lesions, one on
the right and one on the left that progressively cavitate and expel their contents. c Pathology images of one of these cavities showing on the top left the
H&E stained slice and on the right the Masson’s Trichrome stain to illustrate the fibrous cavity wall. In both panels the scale bar is 500 μm. The small black
box in the H&E slice is shown at ×100 with a 10-μm scale bar with acid-fast staining showing the presence of multiple individual bacilli (circled)
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NDH-2 are functionally redundant and inhibition of both kills
Mtb regardless of the presence of fatty acids.
We next sought to understand why fatty acids were toxic for
Δndh-2. Δndh-2 was hypersusceptible to oleic acid (C18:1),
palmitic acid (C16:0), and octanoic acid (C8:0), yet butyric acid
showed only mild toxicity and Δndh-2 grew normally with acetate
and cholesterol (Fig. 5c, Supplementary Fig. 11). Fatty acid
toxicity was thus dependent on chain length, with longer fatty
acids being more toxic. This suggested that NDH-2 might be
needed to balance the ratio of NADH to NAD+, similar to the
function energy dissipating respiratory enzymes have during
aerobic growth with highly reduced carbon sources in other
bacteria32,33. To test this, we expressed LbNox (Supplementary
Fig. 12), an NADH oxidase which converts NADH into NAD+
and water34, in Δndh-2. LbNox reduced sensitivity of Δndh-2 to
oleic acid to the same extent as ectopic expression of Ndh
(Fig. 5c). When we measured NADH and NAD+, we found the
NADH/NAD+ ratio to be higher in Δndh-2 than in WT Mtb
(Fig. 5d). Complementation with ndh and expression of LbNox
reduced the NADH/NAD+ ratio of Δndh-2 to a level similar to
that of WT. However, the NADH/NAD+ ratio of Δndh-2 was
high with and without fatty acids and oleic acid did not cause
NADH to accumulate further (Fig. 5d). The latter argued against
fatty acid toxicity being a consequence of an imbalance in
NADH/NAD+ in Δndh-2. We reasoned that accumulation of
NADH after exposure to oleic acid was prevented by NDH-1.
In contrast to NDH-2, consumption of NADH by NDH-1 is
linked to the export of protons. Sole reliance on NDH-1 might
thus cause an excessive accumulation of periplasmatic protons in
the presence of fatty acids and increase proton motif force (pmf)
to levels that inhibit growth. To test this hypothesis, we used
valinomycin or nigericin, which can reduce pmf by abrogating the
membrane potential and ΔpH, respectively. A narrow range of
valinomycin concentrations indeed supported growth of Δndh-2
with oleic acid. In contrast, no effect was observed with nigericin
or rifampicin (Fig. 5e, f, g). This suggested that a deregulation of
the membrane potential and consequently of pmf causes the oleic
acid sensitivity of Δndh-2 (Fig. 5h).
Drug susceptibility profiles. NDH-2 and cytochrome bc1-aa3
oxidase have been proposed as the targets for several small
molecules with antitubercular activity (Fig. 6a). To determine
how genetic inactivation of NDH-2 and terminal oxidases affects
drug susceptibility of Mtb we profiled ΔctaE-qcrCAB, ΔcydABDC,
and Δndh-2 with (i) the TB drugs rifampicin, isoniazid, ethio-
namide, and ethambutol; (ii) compounds targeting NDH-1
(rotenone, ROT; piericidin A, PIR; pyridaben, PYR), the ribo-
some (linezolid), DNA gyrase (ciprofloxacin), ATP synthase
(bedaquiline, BDQ), and cytochrome bc1 reductase (Q203); (iii)
compounds proposed to target NDH-2 (CFZ, three phenothia-
zines (chlorpromazine, CPZ; trifluoperazine, TFP; thioridazine,
TRZ), and two 2-mercapto-quinazolinones (DDD00853663,
DDD00946831, which correspond to compounds 7 and 10 in the
work that first described them – Supplementary Fig. 1317); and
(iv) the ionophore valinomycin. Susceptibility to rifampicin,
isoniazid, ethionamide, ethambutol, linezolid, and valinomycin
was similar for all strains (Supplementary Tables 3 and 4),
demonstrating that none of the mutants had an unspecific drug
susceptibility defect. Q203 was more potent against ΔcydABDC
than WT (Supplementary Fig. 14A), which is in agreement with
previous reports11,21,35. Q203 showed no activity against ΔctaE-
qcrCAB (Fig. 6g). At least in standard media, Q203 has thus no
phenotypically relevant target other than cytochrome bc1-aa3
oxidase. ΔctaE-qcrCAB, but not ΔcydABDC, proved to be
hypersusceptible to NDH-1 inhibitors (Fig. 6h, Supplementary
Fig. 14B–D, G, H).
2-mercapto-quinazolinones have recently been described as
inhibitors of NDH-217. We found 2-mercapto-quinazolinones to
be potent against WT when oleic acid was present in the media,
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Fig. 4 NDH-2 is essential for growth with fatty acids. Growth with (a) or without fatty acids (b). Data are representative of two independent experiments.
c Growth and survival in the Wayne model of hypoxia. Data are averages of six to eight data points from two independent experiments. Growth and
persistence in lungs (d) and spleens (e) of C57BL/6 mice. Data are averages from four mice per time point and representative of two independent
infections. Error bars correspond to standard deviation. “Comp” stands for complemented. Statistical significance was assessed by one-way ANOVA
followed by post hoc test (Tukey test; GraphPad Prism). Differences between strains in (d) and (e) are not significant. ***P < 0.001; ****P < 0.0001. Source
data are provided as a Source Data file
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yet inactive against WT and Δndh-2 (Fig. 6F, Supplementary
Figs. 14O and 15E, F) in fatty-acid-free media. Chemical and
genetic inhibition of NDH-2 thus lead to similar phenotypes.
Interestingly, both 2-mercapto-quinazolinones were also more
active against ΔcydABDC than WT, which suggests that the
inactivation of both cytochrome bd oxidase and NDH-2 synergize
to inhibit Mtb’s growth (Supplementary Fig. 14E, F). The effect of
these compounds on ΔctaE-qcrCAB growth was negligible
(Supplementary Fig. 14I, J). Δndh-2 was furthermore hypersus-
ceptible to all NDH-1 inhibitors and BDQ (Fig. 6b, c,
Supplementary Fig. 14K, L). However, inactivation of NDH-2
had little, if any, effect on the phenothiazines and CFZ (Fig. 6d, e,
Supplementary Fig. 14M, N). CFZ and phenothiazines also had
similar activities in the presence and absence of oleic acid
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(Supplementary Fig. 15A–D). We concluded that CFZ does not
require activation by NDH-2 to prevent growth of Mtb and that
NDH-2 is not the primary, growth-limiting target of the
phenothiazines.
Discussion
We draw three main conclusions from this work. First, inacti-
vation ofMtb’s cytochrome bc1-aa3 oxidase alone is insufficient to
kill Mtb and could possibly complicate treatment by increasing
cavity formation. Complete genetic inactivation of cytochrome
bc1-aa3 oxidase decreased but did not abolish growth of Mtb
in vitro and in mice. Viability of Mtb without cytochrome bc1-aa3
oxidase was dependent on a functional cytochrome bd oxidase. In
contrast, inactivation of both cytochrome bc1-aa3 oxidase and
cytochrome bd oxidase rapidly killed Mtb in mice. Marmosets
provide an animal model that closely recapitulates human dis-
ease27 with frontline chemotherapy following a similar trajectory
to sterilization in patients28. Strikingly, 2 months of treatment
with the cytochrome bc1-aa3 oxidase inhibitor ND-10885 reduced
inflammation in Mtb-infected marmosets as measured by FDG
uptake but caused no discernable reduction in radiodense volume
of disease. ND-10885 arrested disease progression but not
pathology progression. We have previously demonstrated that
efficacious drugs and drug regimens lead to a progressive decline
in radiodensity corresponding to granulomatous regions in the
lung28,36. Such caseous lesions are severely hypoxic37 and repli-
cation of Mtb under these conditions seems unlikely to be
dependent upon the cytochrome bc1-aa3 oxidase targeted by ND-
10885. Failure to restrict the growth of these hypoxic bacilli likely
leads to progression of disease resulting in cavity formation and
high bacterial titers. Our data also suggest that growth of bacteria
in cellular lesions and macrophages is restricted as lesion density
stabilizes as would be expected if in these microenvironments
Mtb was dependent upon the cytochrome bc1-aa3 oxidase. Cor-
respondingly, ND-10885 had inferior sterilizing ability compared
to even sub-therapeutic regimens such as streptomycin/isoniazid.
Alarmingly, treatment with ND-10885 led to increased cavitation,
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a pathology known to be associated with poor treatment out-
come38. Whether this increase in cavitation is specific to
ND-10885 or will also be caused by other inhibitors of the
cytochrome bc1-aa3 oxidase remains to be determined.
Second, preventing growth ofMtb during infection by targeting
its NADH dehydrogenases requires inactivating three enzymes:
the two NDH-2 enzymes encoded by ndh and ndhA and the
NDH-1 complex encoded by the nuo operon. Previous genetic
analysis concluded that Mtb requires at least one NDH-2 enzyme
to grow8. Our data agree with this prediction as we found Mtb to
require NDH-2 for growth in standard media. Mtb does, how-
ever, not require NDH-2 to grow in fatty-acid-free medium or in
media containing short-chain fatty acids or cholesterol. In mice,
Δndh-2 was attenuated during the acute phase of infection, but it
showed no severe persistence defect. The attenuation that results
from inactivation of both NDH-2 enzymes is thus not funda-
mentally different from what has been observed for a mutant
missing NDH-1 and one of Mtb’s two NDH-2 enzymes. The
activity of specific NDH-2 inhibitors, such as the 2-mercapto-
quinazolinones, phenocopy genetic inactivation of NDH-2
in vitro and will thus likely be inefficacious during infection.
Complementation of Δndh-2 oleic acid hypersusceptibility with
LbNox indicated that NADH generation contributes to long
chain fatty acid toxicity. This can explain why Δndh-2 is less
sensitive to short-chain fatty acids and cholesterol, as the full
oxidation of these carbon sources require a low number of β-
oxidation cycles, while, for example, oleic acid goes through 9
cycles for full oxidation. However, toxicity did not arise from an
unbalanced NADH/NAD+ ratio alone. Rescue with valinomycin,
but not with nigericin, indicated that a deregulation of the
membrane potential was, at least in part, responsible for fatty acid
toxicity. Since NDH-1 is the only NADH dehydrogenase oper-
ating in Δndh-2, the coupling of NADH oxidation with proton
extrusion might have contributed to disturb the membrane
potential and consequently pmf.
Third, phenothiazines and CFZ inhibit growth of Mtb inde-
pendently of NDH-2. Although there is evidence for an effect of
phenothiazines on Mtb’s RC4,13, the potency of these compounds
does not change in response to inactivation of NDH-2. That
phenothiazines act independently of NDH-2 is also supported by
the pleiotropic effects that phenothiazines can have, which
include an impact on membrane permeability and inhibition of
the synthesis of various macromolecules39,40. The growth-
inhibitory activity of CFZ is thought to depend on the oxidative
stress it causes after reduction by NDH-214. Antioxidants can
rescue Mtb’s viability when facing bactericidal CFZ concentra-
tions, which supports this mode of action14. However, WT and
Δndh-2 were equally susceptible to CFZ. Clearly, the activity of
CFZ is not dependent on NDH-2. Conceivably, CFZ might be
reduced by enzymes other than NDH-2, but it is unlikely that
NDH-1 is capable of fulfilling this role, since membranes from
bacteria that only express NDH-1 did not reduce CFZ14.
After the discovery of BDQ, several complexes of Mtb’s RC
were embraced as new targets for TB drug development. This
enthusiasm was supported by new small molecules that inhibit
the cytochrome bc1-aa3 oxidase and drugs or drug candidates that
engage NDH-2. However, the data presented here suggest that
inactivation of either cytochrome bc1-aa3 oxidase or NDH-2
alone may not improve TB chemotherapy. Combinations of
inhibitors targeting either cytochrome bc1-aa3 oxidase and cyto-
chrome bd oxidase or NDH-2 and NHD-1 will be required to
effectively inhibit the respiratory chain of Mtb. In this context,
our work further unveiled genetic and chemical–genetic interac-
tions which could be exploited to improve TB chemotherapy,
namely the interactions between cytochrome bc1-aa3 oxidase and
NDH-1, NDH-2 and ATP synthase, and NDH-2 and cytochrome
bd oxidase. Targeting only cytochrome bc1-aa3 oxidase or NDH-2
might be most valuable for the treatment of infections caused by
mycobacteria, such as M. leprae, that do not possess a functional
cytochrome bd oxidase or NDH-1. This strategy has been suc-
cessfully applied to M. ulcerans, which lacks the alternative
terminal oxidase41.
Methods
Culture conditions. E scherichia coli was used as host for cloning and cultured in
LB. Mtb was generally cultured in Middlebrook 7H9 supplemented with 0.2%
glycerol, 0.05% tyloxapol, and ADNaCl (0.5% BSA, 0.2% dextrose and 0.85% NaCl)
or in Middlebrook 7H10 supplemented with 0.5% glycerol and 10% oleic acid-
albumin-dextrose-catalase (OADC). Fatty acid sensitive strains were cultured in a
modified Sauton’s minimal medium (0.05% potassium dihydrogen phosphate,
0.05% magnesium sulfate heptahydrate, 0.2% citric acid, 0.005% ferric ammonium
citrate, and 0.0001% zinc sulfate) supplemented with 0.05% tyloxapol, 0.4% glu-
cose, 0.2% glycerol, and ADNaCl with fatty-acid-free BSA (Roche). Fatty-acid-free
solid medium contained 1.5% bactoagar (BD) and glycerol was used at a con-
centration of 0.5%. When necessary, antibiotics were added at the following con-
centrations: apramycin 20 μg mL−1, kanamycin 25 μg mL−1, zeocin 25 μg mL−1,
streptomycin 25 μg mL−1, and hygromycin 50 μg mL−1. When needed, atc was
used at a concentration of 500 ng mL−1 (ref. 42).
Mutant construction. All mutants were constructed using protocols and proce-
dures described in detail elsewhere43. Briefly, for mutants of ctaE-qcrCAB, we first
generated a merodiploid by inserting a plasmid at the att-L5 site that expressed
ctaE-qcrCAB under the control of its own promoter (pGMCS-PctaE-qcrCAB). The
WT copy of ctaE-qcrCAB was then replaced by a hygromycin resistance cassette
using a temperature sensitive plasmid leading to ΔctaE-qcrCAB::PctaE-qcrCAB. In
this strain, the only functional copy of ctaE-qcrCAB is located in the attL5 site,
where it can be replaced or deleted by site-specific recombination44. To construct
ctaE-qcrCAB-TetOFF, pGMCS-PctaE-qcrCAB was replaced with pGMCZ-T38S38-
750-ctaE-qcrCAB-SD2, which expresses under control of a reverse TetR; to delete
ctaE-qcrCAB, pGMCS-PctaE-qcrCAB was replaced with pGMCZq17-0 × 0 × ,
which does not contain ctaE-qcrCAB. To complement ΔctaE-qcrCAB the mutant
was transformed with pGMCtKq1-PctaE-qcrCAB, which expressed ctaE-qcrCAB
under the control of its own promoter after integration into the tweety phage
attachment site.
To generate ctaC-tetOFF and ctaD-tetOFF, we have used the dual control
(DUC) strategy, which combines repression of transcription and controlled
proteolysis to deplete the targeted protein45. First merodiploids were generated by
introducing a copy of ctaC under the control of a strong promoter (pGMCS-P750-
ctaC-rv2219) or ctaD-serB2 under the operon’s own promoter (pGMCS-PctaD-
serB2) into the att-L5 site, the WT loci were replaced by a hygromycin resistance
cassette using the phage-mediated recombineering46. These strains were
transformed with a plasmid expressing sspB (pGMCtZq17-TSC10M1-sspB) that
integrated at the tweety phage attachment site. Next, we swapped the construct at
att-L5 with a plasmid where ctaC-DAS or ctaD-DAS are under the control of a Tet-
OFF system (pGMCZ-T38S38-750-ctaC-DAS; pGMCZ-serB2(tr)-T38S38-750-
ctaD-DAS). In the ctaD-TetOFF mutant, serB2 is expressed constitutively. To
generate ΔctaC and ΔctaD, we used ΔctaC::pGMCS-P750-ctaC-rv2219 and ΔctaD::
pGMCS-PctaD-serB2, and swapped the construct at the att-L5 site by an empty
plasmid (pGMCZq17-0×0×) in the case of ΔctaC, and a plasmid expressing serB2
constitutively (pGMCZ-PserB2) in the case of ΔctaD. Complemented strains were
obtained by introducing ctaC under the control of a strong promoter (pGMCtKq1-
P750-ctaC), or ctaD under the control of a strong promoter (pGMCtKq1-Puv15-
ctaD), at the tweety phage attachment site.
ΔcydABDC was constructed by replacing cydABDC with a hygromycin
resistance cassette via homologous recombination. The complemented strain was
obtained by expressing cydABDC under its own promoter (pGMCK-PcydABDC-
SD1) at the att-L5 attachment site. To construct ΔcydABDC ctaE-qcrCAB-TetOFF,
we took advantage of the loxP sites flanking the hygR cassette, which enabled its
removal by expression of Cre recombinase, rendering a hygromycin sensitive
strain. Using this strain as genetic background, we have followed the strategy
previously described to generate a ctaE-qcrCAB-TetOFF strain.
To obtain ndh-2-TetOFF and Δndh-2 we first generated a merodiploid that
expressed ndh under its native promoter (pMPa-Pndh) at attL5. We then
successively replaced the WT copies of ndh and ndhA with hygromycin and
kanamycin resistance cassettes through homologous recombination, respectively,
giving rise to Δndh/ndhA::Pndh. The ndh copy in Δndh/ndhA::Pndh was then
swapped against a plasmid containing ndhA under the control of the DUC system
(pGMCS-0×750-ndhA-DAS)45. The resulting strain transformed with the sspB
expressing vector (pGMCtZq17-TSC10M1-sspB) to generate ndh-2-TetOFF.
Δndh-2 was obtained by swapping the Pndh plasmid against an empty vector
(pGMCZq17-0×0×). The complemented strain was obtained by introducing ndh
under the control of a strong promoter (pGMCtSq19-0×-Puv15-ndh) at the tweety
phage attachment site. For complementation with LbNOX, a codon usage adapted
gene (lbnoxMtb) was ordered from GenScript and cloned into an integrative
plasmid (pGMCgS-0×-Ptb38-LbNOX-FLAG-SD1) that inserts at the Giles
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attachment site. Strains and plasmids used in this work are listed in Supplementary
Tables 5 and 6.
Whole genome sequencing. The genetic identity of ΔctaE-qcrCAB, ΔctaC, ΔctaD,
and Δndh-2 was confirmed by whole genome sequencing (WGS). Between 150 and
200 ng of genomic DNA was sheared acoustically and HiSeq sequencing libraries
were prepared using the KAPA Hyper Prep Kit (Roche). PCR amplification of the
libraries was carried out for 10 cycles. 5–10 × 106 50-bp paired-end reads were
obtained for each sample on an Illumina HiSeq 2500 using the TruSeq SBS Kit v3
(Illumina). Post-run demultiplexing and adapter removal were performed and fastq
files were inspected using fastqc (Andrews S. (2010). FastQC: a quality control tool
for high throughput sequence data. Available at: http://www.bioinformatics.
babraham.ac.uk/projects/fastqc). Trimmed fastq files were then aligned to the
reference genome (M. tuberculosis H37RvCO; NZ_CM001515.1) using bwa
mem47. Bam files were sorted and merged using samtools48. Read groups were
added and bam files de-duplicated using Picard tools and GATK best-practices
were followed for SNP and indel detection49. Gene knockouts and cassette inser-
tions were verified for all strains by direct comparison of reads spanning insertion
points to plasmid maps and the genome sequence. Reads coverage data was
obtained from the software Integrative Genomics Viewer (IGV)50–52. Sequencing
data was deposited in NCBI’s Sequence Read Archive (SRA) database under the
BioProject ID PRJNA532433.
Quantitative PCR. Cultures were grown until mid-exponential phase (OD580nm of
0.5) and harvested with GTC buffer. RNA was extracted using TRIzol reagent
(Invitrogen) and “Quick-RNA™ Miniprep Kit” (Zymo Research), following the
manufacturer’s instructions. DNA was digested with the “Turbo DNA-free kit”
(Invitrogen), and 500 μg of RNA were used to synthesize cDNA using M-MuLV
Reverse Transcriptase (New England BioLabs). qPCR reaction was performed with
LightCycler® 480 SYBR Green I Master (Roche) in the LightCycler® 480 System
(Roche). Primers and probes were designed in the software RealTimeDesign™
(Biosearch Technologies), and ordered from TIB MOLBIOL, LLC. The sequences
of all primers and probes are available in Supplementary Table 7. Probes for genes
of interest were labeled with 5′ 6-FAM/ 3′ BHQ1, while the probe for the reference
gene sigA was labeled with 5′ LC670.
Wayne model of hypoxia. Mtb strains were grown in Dubos broth base (Difco)
supplemented with 0.05% tyloxapol, 0.75% dextrose, 0.5% fatty-acid-free BSA
(Roche), and 0.85% NaCl until mid-log phase (OD580 approx. 0.4). Single cell
suspensions were prepared in the same medium to a final OD580 of 0.05. In total,
20 mL of the single-cell suspension were aliquoted into flat-bottomed tubes each
equipped with a black cap (Wheaton) and a magnetic stirrer. Paraplast wax
(Kendall) was used to seal the tubes. One tube of each strain was further supple-
mented with methylene blue (1.3 μg mL−1), which served as a hypoxia indicator.
Cultures were incubated at 37 °C on a magnetic platform at 130 rpm. OD580 was
measured for 40 days and bacteria were plated for CFU at the indicated time points
in fatty-acid-free modified Sauton’s medium.
Growth with fatty acids. Strains were grown in modified Sauton’s minimal med-
ium until mid-log phase (OD580 0.6–0.8). Bacteria were collected and resuspended in
the same medium to generate single-cell suspensions. Modified Sauton’s minimal
medium was supplemented with fatty acids or cholesterol at the following final
concentrations: acetic acid 125mM, butyric acid 25mM, octanoic acid 2mM, pal-
mitic acid 500 μM, oleic acid 1mM (1.5mM in the assays with lbnox), and cho-
lesterol 125 μgmL−1. Octanoic acid, palmitic acid, and oleic acid were solubilized in
DMSO, while cholesterol was solubilized in a 1:1 tyloxapol:ethanol solution and then
added to the medium. Serial dilutions of each fatty acid or cholesterol (2-fold) were
made in 96-well plates. Single-cell suspension of Mtb strains were added to a final
volume in each well of 200 μL and an OD580 of 0.01. Plates were kept at 37 °C and
OD580 readings were carried out after 14 days of incubation. Sauton’s minimal
medium supplementation with the corresponding solvents at the higher con-
centration constituted the control and was used to normalize the final OD580 values.
Immunoblot analysis of cytosolic proteins. Protein extracts were prepared from
WT, Δndh-2, and Δndh-2::lbnox-Flag cultures. Bacteria were harvested by cen-
trifugation, washed with phosphate-buffered saline (PBS) with 0.05% Tween 80
and resuspended in 500 µL PBS, 1xprotease inhibitor cocktail (Roche). Bacterial
lysis was performed by bead-beating three times at 4500 rpm for 30 s with 0.1 mm
Zirconia/Silica beads. After centrifugation (11,000 × g/10 min, 4 °C), the super-
natant was filtered through a 0.2-µm SpinX column (Corning). Protein con-
centrations were determined using a DC Protein Assay Kit (Bio-Rad). For
immunoblots, 30 µg protein were loaded and separated through SDS-PAGE,
transferred to nitrocellulose membranes and incubated with anti-Flag (Sigma-
Aldrich; 1∶400 dilution) and anti-PrcB (1∶15,000 dilution). Odyssey Infrared
Imaging System (LI-COR Biosciences) was used to detect the proteins.
NADH/NAD+ratio determination. Strains were grown in modified Sauton’s
minimal medium until an OD580 of 0.5, and resuspended in the same medium
supplemented with DMSO or oleic acid (500 μM). Bacteria were harvested after 6 h
of further incubation. The NADH/NAD + ratio was determined using the com-
mercial kit Fluoro NAD (Cell Technnology), following the manufacturer’s
instructions. Protein quantification via Pierce BCA Protein Assay Kit (Thermo
Scientific) was used to normalize NADH and NAD + concentrations.
Drug susceptibility profiling. Depending on the strain, bacteria were cultured in
7H9, modified Sauton’s minimal medium, or modified Sauton’s minimal medium
supplemented with oleic acid (200 μM) until mid-log phase (OD580 0.6–0.8) in
100 mL roller bottle cultures. Bacteria were washed once in fresh medium and
single-cell suspensions were prepared to a final OD580 nm of 0.01 in the same
medium. Compounds were solubilized in DMSO and dispensed into 384-well
plates using a D300e Digital Dispenser (HP). DMSO at a final concentration of 1%
was used as no-drug control. In all, 50 μL of single-cell suspension was pipetted to
each well and cultures were incubated for 12 days at 37 °C. Final OD580 values were
normalized to no-drug control.
Mouse infection. All mouse experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health, with approval from the Institutional Animal Care and Use Committee of
Weill Cornell Medicine. Female C57BL/6 mice (Jackson Labs) were infected with
~100–200 CFU/mouse using an Inhalation Exposure System (Glas-Col). Single-cell
suspensions of early mid-log phase bacteria were prepared in PBS with 0.05%
Tween 80, and then resuspended in PBS. When indicated, doxycycline containing
food (2,000 p.p.m., Research Diets) was given to mice starting at the indicated
time-points to induce protein depletion. Lungs and spleen were homogenized in
PBS and plated on 7H10 plates or, when necessary, in solid modified Sauton’s
minimal medium to determine CFU/organ at the indicated time points.
Marmoset Infection. Common marmosets (Callithrix jacchus) breeding and all
procedures were performed in accordance with the recommendations of the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health.
The NIAID Animal Care and Use Committee approved the experiments described
herein (Protocol LCIM-9, Permit issued to NIH as A-4149-01). Prior to infection,
marmosets were transferred to a BSL-3 animal facility approved for the contain-
ment of Mtb and handled as previously described27,28. Marmosets were aged
between 2 and 5 years, of both genders, and ranged in weight from ~300 to 500 g at
infection with Mtb strain CDC1551 with a nose-only aerosol generated in a BANG
nebulizer through a CH Technologies inhalation system (Westwood, NJ). The dose
was 10–25 CFU per animal. Infection progress was monitored by PET/CT, scanned
twice prior to starting the treatment and every 2 weeks during 8 weeks of treat-
ment. Mtb exposure in this experiment resulted in an average of 10 lesions/mar-
moset (SD= 4) as assessed by PET/CT at 5–6 weeks and 5 marmosets among 15
individuals were randomly assigned receive ND-10885. At necropsy, samples of all
PET/CT identified lung lesions, pulmonary lymph nodes, and other possibly
involved organs were weighed, homogenized, and plated in triplicate onto M7H11
agar supplemented with albumin, oleic acid, dextrose, cycloheximide (0.03 μg/mL),
carbenicillin (0.05 μg/mL), polymixin B (25 μg/mL), trimethoprim (20 μg/mL), and
activated charcoal powder (0.4% w/v) to enumerate bacterial CFU/structure.
Plasma pharmacokinetics, dose finding, and drug treatment in marmosets.
The marmoset dose of ND-10885 was optimized in order to achieve a ratio of Area
Under the Curve to MIC (AUC/MIC) well above the AUC/MIC at which max-
imum efficacy was observed in a murine model of Mycobacterium avium infec-
tion29. This corresponded to an AUC of 50 µg h/mL. In marmosets, ND-10885
appears to undergo CYP-mediated metabolism (Supplementary Fig. 9) and solu-
bility limited bioavailability. To increase exposure while alleviating the need for
higher dosing, we co-administered 1-aminobenzotriazole (ABT, Cayman Chemical,
Ann Arbor, MI) at 20 mg/kg31.
ND-10885 was formulated as an aqueous suspension stepwise in 10% w/v 2-
hydroxypropyl-β-cyclodextrin, 10% w/v lecithin, 15% w/v saccharine, and 3% v/v
Grape flavoring (Paddock Laboratories, Minneapolis, MN) and was administered
at 1 mL/kg as an oral suspension for 2 months (50 mean dose days) to fed, hand-
caught, awake, and restrained marmosets as previously described28. Doses used in
pharmacokinetic and tolerability experiments included 20 mg/kg and 40 mg/kg
with or without 20 mg/kg ABT administered both the previous day and 30 min
prior to ND-10885. Discolored urine suggesting possible myoglobinuria was
observed near the termination of the 20-dose tolerability study at 20 mg/kg, thus
lower doses were used during the efficacy study. We employed a therapeutic drug
monitoring approach during treatment to allow for dose escalation if the target
AUC of 50 µg h/mL was not achieved. Treatment commenced with 20 mg/kg ABT
1 day prior and continued daily 30 min prior to the ND-10885 dose. Two
marmosets began treatment with once daily 5 mg/kg ND-10885 and were escalated
to 12.5 mg/kg daily (BI61 and M269). BI31 began daily 5 mg/kg ND-10885, was
escalated to 12.5 mg/kg daily, and finally to 12.5 mg/kg twice daily in order to
achieve an average AUC of 50 µg h/mL. Two marmosets were treated with the
maximum dose of 12.5 mg/kg twice daily (BL24 and BI73). At the time of necropsy,
tissues and lung lesions were sampled and processed for quantitation of ND-10885
as previously described27,28,53.
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PET/CT data analysis. PET/CT files were co-registered and serial scans were
aligned in MIMMaestro (v. 6.2, MIM Software Inc, Cleveland, Ohio), and each lesion
was individually defined within a three-dimensional region of interest (ROI) on each
serial scan. The numerical output of these ROIs including the radiodense volumes
(−100 to 200 HU) from the CT images and [18F]-2-fluoro-2-deoxyglucose (FDG)
uptake (expressed as TGA) for the ROI voxels with a standardized uptake value
(SUV) ≥ 2 were assessed for change in subsequent scans28. Three readers performed
the extractions independently for each set of animal lesions and the data presented are
an average of the resulting readings. The CFU data for each lesion or structure were
aligned to the PET/CT and histology data to using the prepared necropsy maps and
logs to evaluate the response of the individual lesion types during treatment.
Quantitation of ND-10885 in plasma and TB lesions. ND-10885 levels in
plasma, tissues, and lung lesions were measured by LC-MS/MS in electrospray
positive-ionization mode (ESI+) on a Sciex Qtrap 4000 triple-quadrupole mass
spectrometer combined with an Agilent 1260 HPLC using Analyst software.
Chromatography was performed with an Agilent Zorbax SB-C8 column (2.1 ×
30mm; 3.5-µm particle size) using a reverse phase gradient elution. In all, 0.1%
formic acid in Milli-Q deionized water was used for the aqueous mobile phase and
0.1% formic acid in acetonitrile (ACN) for the organic mobile phase. Multiple-
reaction monitoring (MRM) of parent/daughter transitions in electrospray positive-
ionization mode (ESI+) was used to quantify ND-10885. DMSO stock of ND-10885
was serial diluted in blank K2EDTA plasma (Bioreclammation) to create standard
curves and quality control samples. ND-10885 was extracted by combining 20 µL of
spiked plasma or study samples and 200 µL of acetonitrile/methanol 50/50 protein
precipitation solvent containing 20 ng/mL Verapamil internal standard (IS).
Extracts were vortexed for 5 min and centrifuged at 4000 RPM for 5 min. The
supernatants were analyzed by LC-MS. Verapamil IS was sourced from Sigma-
Aldrich. The following MRM transitions were used for ND-10885 (322.1/133) and
Verapamil (455.4/165.2). Sample analysis was accepted if the concentrations of the
quality control samples were within 20% of the nominal concentration.
Quantification and statistical analysis. Generation of graphics and data analyses
were performed in Prism version 7.0 software (GraphPad), Spotfire version
7.8.0 software (TIBCO), and MIM Encore (Version 6.7.8, MIM Software Inc.).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors confirm that all relevant data are included in the paper and/or its
supplement. Sequencing data can be accessed in NCBI’s Sequence Read Archive (SRA)
database under the BioProject ID PRJNA532433. Plasmids and strains generated in this
study will be available through material transfer agreements upon reasonable request to
the corresponding author.
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